Welcome to our dedicated page for Cartesian SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cartesian Therapeutics, Inc. (NASDAQ: RNAC) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Cartesian describes itself as a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, with lead CAR-T programs Descartes-08 and Descartes-15. Its SEC filings offer detailed information on clinical development, financial position, governance and risk factors that complement the company’s press releases.
Investors researching RNAC can use this page to review current and historical Forms 10-K and 10-Q for audited and interim financial statements, discussion of operations, and disclosures about the Descartes-08 and Descartes-15 programs. Form 8-K filings provide timely updates on material events, such as clinical data announcements, trial initiations or pauses, changes in development priorities, financial results releases, board appointments and executive transitions, amendments to bylaws, and updates to the company’s code of business conduct and ethics.
Cartesian’s filings also document equity awards and inducement grants, board and committee roles, and other compensation arrangements, which can be relevant for understanding governance and incentive structures. Where applicable, proxy materials describe director elections and governance policies, and registration statements outline the terms of any registered offerings.
Stock Titan enhances these RNAC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important disclosures related to Descartes-08’s Phase 3 AURORA trial in myasthenia gravis, expansion into myositis and pediatric indications, and the status of Descartes-15. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, and 10-Ks appear promptly, while Form 4 insider transaction reports can be reviewed to see equity transactions by directors and officers as disclosed to the SEC.
By combining original SEC documents with AI-generated explanations, this page helps users interpret Cartesian Therapeutics’ regulatory reporting, understand how clinical and strategic developments are reflected in official filings, and follow the evolution of RNAC as a clinical-stage biotechnology issuer.
CARTESIAN THERAPEUTICS INC ownership update: institutional investor FMR LLC reports beneficial ownership of 799,743 shares of Common Stock, representing 3.0% of the class as of 03/31/2026. The filing also lists Abigail P. Johnson with dispositive power over the same 799,743 shares.
The filing is an Amendment No. 4 to a Schedule 13G/A and includes a reference to a 13d-1(k) agreement in Exhibit 99 and a power of attorney incorporated by reference.
Cartesian Therapeutics, Inc. reported a first-quarter 2026 net loss of $39.2 million, wider than the prior year, as it increased investment in its lead cell therapy programs and recorded a higher fair value for contingent value rights.
Revenue was minimal at $0.1 million, all from a government grant, with no collaboration revenue recognized. Research and development expenses rose to $19.5 million, driven mainly by Phase 3 work on Descartes-08 for myasthenia gravis, while general and administrative costs declined to $7.1 million.
The company ended the quarter with $120.4 million in cash, cash equivalents and restricted cash and raised about $14.6 million through an at-the-market stock offering, and believes this liquidity will fund planned operations for at least the next 12 months.
Cartesian Therapeutics reported first quarter 2026 results and updated progress on its Descartes-08 cell therapy pipeline. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, which the company expects will fund planned operations into mid-2027, including completion of the ongoing Phase 3 AURORA trial in myasthenia gravis.
For the quarter, total revenues were $78 thousand versus $1.1 million a year earlier, while research and development expenses rose to $19.5 million from $14.7 million, and general and administrative expenses declined to $7.1 million from $8.3 million. Net loss widened to $39.2 million, or $1.46 per basic share, compared with $17.7 million, or $0.68 per basic share, in the prior-year period.
The company highlighted ongoing enrollment in the randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody–positive myasthenia gravis, initiation of the Phase 2 TRITON trial in multi-refractory myositis, and enrollment of multiple patients in the pediatric Phase 1/2 HELIOS trial in juvenile dermatomyositis. Descartes-08 is an autologous BCMA-targeting CAR-T designed for outpatient administration without preconditioning chemotherapy and has received multiple U.S. FDA designations, including Orphan Drug and Regenerative Medicine Advanced Therapy designations in myasthenia gravis and Rare Pediatric Disease designation in juvenile dermatomyositis.
Cartesian Therapeutics, Inc. will hold its 2026 Annual Meeting virtually on June 12, 2026 at 10:00 a.m. Eastern Time. Stockholders will vote to elect three Class I directors to terms ending in 2029, approve on a non-binding basis executive compensation, and ratify Ernst & Young LLP as auditor for 2026.
Holders of 29,302,729 shares of common stock outstanding as of April 14, 2026 are entitled to one vote per share and may vote by internet, telephone, mail, or during the virtual meeting. The proxy also outlines board structure, committee responsibilities, and a pay program emphasizing variable, equity-based compensation tied to company performance.
Cartesian Therapeutics, Inc. insider reporting shows a trust-related conversion of preferred stock into common stock. On April 2, 2026, Seven One Eight Three Four Irrevocable Trust elected to convert a portion of its Series A Non-Voting Convertible Preferred Stock into 758,001 shares of common stock at a stated conversion price of $0.0000 per share, all held indirectly with Elizabeth Hoge acting as trustee.
Following the conversion, the Trust holds 5,313,261 shares of common stock and 33,662.224 shares of Series A Non-Voting Convertible Preferred Stock, with the remaining preferred shares subject to a beneficial ownership limitation. A separate indirect holding reflects 506,999 shares of common stock held by Hoge's spouse. Footnotes state these securities stem from merger consideration and a private placement completed in November 2023.
Cartesian Therapeutics, Inc. insider filing shows a trust converting preferred stock into common shares. On April 2, 2026, a trust for the benefit of Murat Kalayoglu’s spouse and children exercised 22,740.03 shares of Series A Non-Voting Convertible Preferred Stock to acquire 758,001 shares of common stock at a conversion price of $0.00 per share.
After the transaction, the trust held 33,662.224 shares of the preferred stock and 5,313,261 shares of common stock indirectly. Murat Kalayoglu also held 506,999 shares of common stock directly. The filing reflects a derivative exercise and conversion, not an open-market purchase or sale.
An investor group led by Murat Kalayoglu updated its ownership in Cartesian Therapeutics, Inc. common stock. The group now reports beneficial ownership of 5,833,971 shares, about 19.9% of the company’s common stock, based on 28,544,728 shares outstanding as of March 31, 2026.
On March 31, 2026, Murat Kalayoglu resigned from the board of directors. On April 2, 2026, a trust affiliated with him converted 22,740.030 shares of Series A Preferred Stock into 758,001 shares of common stock, contributing to the currently reported ownership levels across the reporting persons.
Cartesian Therapeutics, Inc. reported that board member Murat Kalayoglu, M.D., Ph.D. has informed the company he will resign from its Board of Directors, effective March 31, 2026, to pursue other opportunities.
He currently serves as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee, and will cease serving on these committees in connection with his resignation. The company states that his decision was not due to any disagreement with the company regarding its operations, policies, or practices and expresses appreciation for his service since 2023.
Cartesian Therapeutics director Michael Singer reported a bona fide gift of 6,555 shares of Common Stock on March 13, 2026. The gift was made at no stated price and is classified as a non-market disposition rather than a sale.
After the gift, Singer directly holds 49,578 shares. He also reports additional indirect holdings in Cartesian Therapeutics through several trusts, a spouse account, and custodial accounts for his children under UTMA.
Cartesian Therapeutics, Inc. disclosure: multiple Squarepoint entities report beneficial ownership stakes in Common Stock totaling between 30,949 and 2,209,601 shares per entity as filed on 03/09/2026.
The filing lists Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Ltd each holding 2,209,601 shares (reported 8.34% of the class), Squarepoint Master Fund Limited holding 2,178,652 shares (8.22%), and Squarepoint Core Master Fund Limited holding 30,949 shares (0.12%).